Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders
Status:
Completed
Trial end date:
2016-05-09
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label trial designed to assess the pharmacokinetics, safety,
tolerability, and preliminary efficacy of 3 multiple ascending doses of Cannabidiol Oral
Solution in a sequential fashion.
Participants will be pediatric (aged 1-17, inclusive), experiencing treatment-resistant
seizures, and satisfy all inclusion/exclusion criteria.